Leaders, innovators, scientists, doctors, patients, enthusiasts, and dignitaries in the psychedelic space are invited to attend a virtual Q&A session by the Clearmind Management, focused on the potential treatment of alcohol use and binge drinking based on its psychoactive molecule MEAI, on March 30, 2022.
Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), is a psychedelic medicine biotech company engaged in the discovery and development of novel psychedelic-derived therapeutics. Adi Zuloff-Shani, PhD, Clearmind’s Chief Executive Officer, will discuss the various possibilities of therapeutics development for excessive alcohol consumption and related mental disorders, in heavily regulated environments.
Visionaries and innovators in the psychedelic space will discuss the psychedelic therapies and treatments for excessive alcohol consumption and mental disorders based on its Psychoactive Molecule MEAI. The expert panel at Clearmind ManAgement will solve user queries and discuss the therapeutic treatments of excess alcohol use and mental disorders.
For more information, please visit https://ibn.fm/BLHsB